Top

Published in:

01-08-2018 | Original Article

Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: a randomized clinical trial

Authors: Natália Guimarães Barbosa, Amanda Katarinny Goes Gonzaga, Luzia Leiros de Sena Fernandes, Aldilane Gonçalves da Fonseca, Salomão Israel Monteiro Lourenço Queiroz, Telma Maria Araújo Moura Lemos, Éricka Janine Dantas da Silveira, Ana Miryam Costa de Medeiros

Published in: Lasers in Medical Science | Issue 6/2018

Abstract

The aim of this study was to evaluate the efficacy of low-level laser therapy (LLLT) and alpha-lipoic acid (ALA) in the treatment of burning mouth syndrome (BMS) and secondary oral burning (SOB) by unstimulated sialometry, symptom assessment, and measurement of salivary TNF-α levels. Forty-four patients were randomized into four treatment groups: BMS/laser (n = 10), BMS/ALA (n = 5), SOB/laser (n = 15), and SOB/ALA (n = 14). The control group consisted of eight healthy female subjects. Unstimulated salivary flow was measured before and after treatment, and the collected saliva was stored at − 20 °C for the analysis of TNF-α. Symptoms were evaluated before and after treatment using a pain visual analog scale. Most patients were women (81.8%) during menopause (72.2%). LLLT and ALA were efficient in increasing salivary flow only in BMS but provided symptom relief in both conditions. TNF-α levels did not differ between patients with BMS and SOB or between those patients and the control group. No differences were observed in posttreatment TNF-α levels in either condition. The results of this study suggest that LLLT and ALA are efficient therapies in reducing burning mouth symptoms, with LLLT being more efficient than ALA.

Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalagia 33:629–808CrossRef

Soares MS, Chimenos-Küstner E, Subirá-Pifarrè C, Rodríquez de Rivera-Campillo ME, López-López J (2005) Association of burning mouth syndrome with xerostomia and medicines. Med Oral Patol Oral Cir Bucal 10:301–308PubMed

López-Jornet P, Camacho-Alonso F, Andujar-Mateos P, Sánchez-Siles M, Gómez-Garcia F (2010) Burning mouth syndrome: an update. Med Oral Patol Oral Cir Bucal 15:e562–e568CrossRefPubMed

Klasser GD, Epstein JB, Villines D (2011) Diagnostic dilemma: the enigma of an oral burning sensation. J Can Dent Assoc 77:b143

Lee YC, Hong IK, Na SY, Eun YG (2015) Evaluation of salivary function in patients with burning mouth syndrome. Oral Dis 21:308–313CrossRefPubMed

Poon R, Su N, Ching V, Darling M, Grushka M (2014) Reduction in unstimulated salivary flow rate in burning mouth syndrome. Br Den J 217:E14CrossRef

Spadari F, Venesia P, Veronesi G, Costantino D, Croveri F, Farronato D et al (2015) Low basal salivary flow and burning mouth syndrome: new evidence in this enigmatic pathology. J Oral Pathol Med 44:229–233CrossRefPubMed

Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis MPD (2015) The prevalence of burning mouth syndrome: a population-based study. Br J Dermatol 172:1654–1656CrossRefPubMedPubMedCentral

Woda A, Dao A, Gremeau-Richard C (2009) Steroid dysregulation and stomatodynia (burning mouth syndrome). J Orofac Pain 23:202–210PubMed

10.

Boras VV, Brailo V, Lukac J, Kordic D, Blazic-Potocki Z (2006) Salivary interleukin-6 and tumor necrosis factor alpha in patients with burning mouth syndrome. Oral Dis 12:353–355CrossRefPubMed

11.

Simsic D, Pezelj-Ribaric S, Grzic R, Horvat J, Brumini G, Muhvic-Urek M (2006) Mediat Inflamm 2006:1–4CrossRef

12.

Pezelj-Ribaric S, Kgiku L, Brumini G, Urek MM, Antonic R, Kuis D et al (2013) Proinflammatory cytokine levels in saliva in patients with burning mouth syndrome before and after treatment with low-level laser therapy. Lasers Med Sci 28:297–301CrossRefPubMed

13.

Pekiner FN, Demirel GY, Gümrü B, Ozbayrak S (2008) Serum cytokine and T regulatory cell levels in patients with burning mouth syndrome. J Oral Pathol Med 37:528–534CrossRefPubMed

14.

Pekiner FN, Gümrü B, Demirel GY, Özbayrak S (2009) Burning mouth syndrome and saliva: detection of salivary trace elements and cytokines. J Oral Pathol Med 38:269–275CrossRefPubMed

15.

Suh KI, Kim YK, Kho HS (2009) Salivary levels of IL-1beta, IL-6, IL-8, and TNF-alpha in patients with burning mouth syndrome. Arch Oral Biol 54:797–802CrossRefPubMed

16.

Kho HS, Chang JY, Kim YY, Kim Y (2013) MUC1 and Toll-like receptor-2 expression in burning mouth syndrome and oral lichen planus. Arch Oral Biol 58:837–842CrossRefPubMed

17.

Kato IT, Pellegrini VD, Prates RA, Ribeiro MS, Welter NU, Sugaya NN (2010) Low-level laser therapy in burning mouth syndrome patients: a pilot study. Photomed Laser Surg 28:835–839CrossRefPubMed

18.

Santos LFC, Carvalho AA, Leão JC, Cruz Peres DE, Castro JF (2011) Effect of low-level laser therapy in the treatment of burning mouth syndrome: a case series. Photomed Laser Surg 29:793–796CrossRef

19.

Yang HW, Huang YG (2011) Treatment of burning mouth syndrome with a low-level energy diode laser. Photomed Laser Surg 29:123–125CrossRefPubMed

20.

Santos LF, Andrade SC, Nogueira GE, Leão JC, Freitas PM (2015) Phototherapy on the treatment of burning mouth syndrome: a prospective analysis of 20 cases. Photochem Photobiol 91:1231–1236CrossRef

21.

Arbabi-Kalati F, Bakhshani NM, Rasti M (2015) Evaluation of the efficacy of low-level laser in improving the symptoms of burning mouth syndrome. J Clin Exp Dent 7:e524–e527CrossRefPubMedPubMedCentral

22.

Spanemberg JC, López-López J, Figueiredo MA, Cherubini K, Salum FG (2015) Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: a randomized, controlled trial. J Biomed Opt 20:098001CrossRefPubMed

23.

Miziara I, Chagury A, Vargas C, Freitas L, Mahmoud A (2015) Therapeutic options in idiopathic burning mouth syndrome: literature review. Int Arch Otorhinolaryngol 19:86–89CrossRefPubMed

24.

Femiano F, Gombos F, Scully C, Busciolano M, De Luca P (2000) Burning mouth syndrome (BMS): controlled open trial the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis 6:274–277CrossRefPubMed

25.

Femiano F, Scully C (2002) Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med 31:267–269CrossRefPubMed

26.

Femiano F, Gombos F, Scully C (2004) Burning mouth syndrome (BMS): open trial of psychotherapy alone, medication with alpha-lipoic acid (thioctic acid), and combination therapy. Med Oral 9:8–13PubMed

27.

Moraes M, Amaral Bezerra BA, Rocha Neto PC, Oliveira Soares AC, Pinto LP, Lisboa Lopes Costa A (2012) Randomized trials for the treatment of burning mouth syndrome: an evidence-based review of the literature. J Oral Pathol Med 41:281–287CrossRefPubMed

28.

Cavalcanti DR, Silveira FR (2009) Alpha lipoic acid in burning mouth syndrome—a randomized double-blind placebo-controlled trial. J Oral Pathol Med 38:254–261CrossRefPubMed

29.

Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S (2009) Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. Eur J Pain 13:492–496CrossRefPubMed

30.

López-Jornet P, Camacho-Alonso F, Leon-Espinosa S (2009) Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. J Oral Rehabil 36:52–57CrossRefPubMed

31.

Slebioda Z, Szponar E (2014) Burning mouth syndrome—a common dental problem in perimenopausal women. Prz Menopauzalny 13:198–202PubMedPubMedCentral

32.

Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA (2003) Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 14:275–291CrossRefPubMed

33.

Danhauer SC, Miller CS, Rhodus NL, Carlson CR (2002) Impact of criteria-based diagnosis of burning mouth syndrome on treatment outcome. J Orofac Pain 16:305–311PubMed

34.

Gurvita GE, Tan A (2013) Burning mouth syndrome. World J Gastroenterol 19:665–672CrossRef

35.

Adamo D, Celentano A, Ruoppo E, Cucciniello C, Pecoraro G, Aria M et al (2015) The relationship between sociodemographic characteristics and clinical features in burning mouth syndrome. Pain Med 16:2171–2179CrossRefPubMed

36.

Lima ENA, Barbosa NG, Santos ACS, Lemos TMAM, Souza CM, Trevilatto PC et al (2016) Comparative analysis of psychological, hormonal, and genetic factors between burning mouth syndrome and secondary oral burning. Pain Med:1–10

37.

Meurman JH, Tarkkila L, Tittinen A (2009) The menopause and oral health. Maturitas 63:56–62CrossRefPubMed

38.

Demarosi F (2013) Síndrome della bocca urente (manuscris)

39.

Balasubramaniam R, Klasser GD, Delcanho R (2009) Separating oral burning from burning mouth syndrome: unravelling a diagnostic enigma. Aust Dent J 54:293–299CrossRefPubMed

40.

Salort-Llorca C, Mínquez-Serra MP, Silvestre FJ (2008) Drug-induced burning mouth syndrome: a new etiological diagnosis. Med Oral Patol Cir Bucal 13:E167–E170

41.

Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S et al (2003) Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 101:149CrossRefPubMed

42.

Grushka M, Epstein JB, Gorsky M (2003) Burning mouth syndrome and other oral sensory disorders: a unifying hypothesis. Pain Res Manag 8:133–135CrossRefPubMed

43.

Hershkovic O, Nagler RM (2004) Biochemical analysis of saliva and taste acuity evaluation in patients with burning mouth syndrome, xerostomia and/or gustatory disturbances. Arch Oral Biol 49:515–522CrossRef

44.

Granot M, Nagler RM (2005) Association between regional idiopathic neuropathy and salivary involvement as the possible mechanism for oral sensory complaints. J Pain 6:581–587CrossRefPubMed

45.

Souza FT, Amaral TM, Santos TP, Abdo EN, Aguiar MC, Teixeira AL et al (2012) Burning mouth syndrome: a therapeutic approach involving mechanical salivary stimulation. Headache 52:1026–1034CrossRefPubMed

46.

Imura H, Shimada M, Yamazaki Y, Sugimoto K (2016) Characteristic changes of saliva and taste in burning mouth syndrome patients. J Oral Pathol Med 45:231–236CrossRefPubMed

47.

Sreebny LM (2000) Saliva in health and disease: an appraisal and update. Int Dent J 50:140–161CrossRefPubMed

48.

Leung L, Cahill CM (2010) TNF-alpha and neuropathic pain—a review. J Neuroinflammation 7:27CrossRefPubMedPubMedCentral

49.

Gomes MB, Negrato CA (2014) Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 6:1–18CrossRef

Title: Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: a randomized clinical trial
Authors: Natália Guimarães Barbosa
Amanda Katarinny Goes Gonzaga
Luzia Leiros de Sena Fernandes
Aldilane Gonçalves da Fonseca
Salomão Israel Monteiro Lourenço Queiroz
Telma Maria Araújo Moura Lemos
Éricka Janine Dantas da Silveira
Ana Miryam Costa de Medeiros
Publication date: 01-08-2018
Publisher: Springer London
Published in: Lasers in Medical Science / Issue 6/2018
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-018-2472-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: a randomized clinical trial

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

LED session prior incremental step test enhance VO2max in running

Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component

Comparative effect of photobiomodulation associated with dexamethasone after sciatic nerve injury model

ROS-induced autophagy reduces B16F10 melanoma cell proliferative activity

ENAP vs LANAP: assessment of revascularization using ultrasound Doppler flowmetry—a split-mouth randomized controlled clinical trial

Effects of laser therapy on patients who underwent rapid maxillary expansion; a systematic review